Fortified S-Allyl L-Cysteine: Animal Safety, Effect on Retinal Ischemia, and Role of Wnt in the Underlying Therapeutic Mechanism

Table 1

Body weight (g) changes after oral gavage for 4 weeks of preischemia daily doses of Vehicle or SAC treatment.

Time/group	Vehicle	SAC 0.18 mg	SAC 0.018 mg	SAC 0.0018 mg
Baseline	220.2 ± 18.1	217.0 ± 18.2	221.8 ± 16.9	224.0 ± 18.1
Week 1	258.2 ± 16.0	257.3 ± 14.5	262.2 ± 15.8	269.5 ± 18.2
Week 2	282.2 ± 13.8	280.0 ± 8.3	304.5 ± 14.7	292.0 ± 12.1
Week 3	324.0 ± 12.3	310.7 ± 6.7	325.7 ± 9.1	328.2 ± 8.2
Week 4	321.0 ± 9.5	322.3 ± 8.7	323.3 ± 12.5	330.7 ± 17.7

Body weights (BWs) were measured at the baseline (0 week) or 1/2/3/4 weeks after oral gavage of preischemia administration of daily doses of vehicle or SAC (0.18, 0.018 or 0.0018 mg) treatment. The results are recorded without following ischemia and represented as mean ± S.E.M. (n = 6∼11). SAC, S-allyl L-cysteine.